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Abstract 
Summary.  
Objectives: 
To evaluate the clinical accuracy of antiphospholipid antibody (aPL) specificities both individually 
and/or in combination, in a wide cohort of systemic lupus erythematosus (SLE) patients in an attempt to 
identify a panel of tests that may provide the best accuracy for diagnosing antiphospholipid syndrome 
(APS).  Patients and Methods:This study included 230 patients (218 women, mean age 
42.7 ± 11.9 years, mean disease duration 12.2 ± 8.7 years), all fulfilling the 1982 criteria for SLE. All 
patients were tested for lupus anticoagulant (LA), anti-cardiolipin (aCL), anti-β 2glycoprotein I (anti-
β2GPI), solid phase anti-prothrombin (aPT), anti-phosphatidylserine/prothrombin (aPS/PT), and anti-
phosphatidylethanolamine (aPE) antibodies. Sensitivity, specificity and predictive values were 
calculated. The diagnostic accuracy for each combination of tests was assessed by ROC and their area 
under the curve analysis as well as by the Youden’s index (YI). Results:Testing for six aPL derived 23 
possible combinations of results. Among them, LA + anti-β 2GPI + aPS/PT had the best diagnostic 
accuracy for APS as a whole and individually for both thrombosis and pregnancy loss (AUC 0.712, OR 
3.73 [95% CI 1.82–5.38],P = 0.0001, YI = 0.32 and AUC 0.709, OR 3.75 [95% CI 2.13–
6.62], P = 0.0001, YI = 0.37 and AUC 0.677, OR 4.82 [95% CI 2.17–10.72], P = 0.0007, YI = 0.38, 
respectively) and the best specificity when compared with all the other obtainable combination of tests. 
Triple positivity for LA + anti-β2GPI + aPS/PT was more strongly associated with clinical events 
(thrombosis and/or PL) when compared with double or single positivity (OR 23.2 [95% CI 2.57–46.2] 
vs. OR 7.3 [95% CI 2.21–25.97], OR 5.7 [95% CI 2.12–17.01] or OR 3.11 [95% CI 1.56–7.8] for single 
positivity for LA, aPS/PT and anti-β2GPI, respectively). Conclusions:Combining LA, anti-β 2GPI and 
aPS/PT improves the diagnostic power and helps in stratifying the risk for each patient, according to 
their aPL profile. 
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The antiphospholipid syndrome (APS) is a thrombophilic disorder characterized by arterial and/or 
venous thrombosis and/or pregnancy loss, associated with the presence of a specific group of 
autoantibodies, the so-called antiphospholipid antibodies (aPL). In clinical practice, anticardiolipin 
(aCL) and anti-β2glycoprotein I (anti-β2GPI) antibodies detected by an enzyme linked immunosorbent 
assay (ELISA) and the lupus anticoagulant (LA) detected by clotting assays are the most widely used 
tests for the detection of aPL. In addition, positivity for one or more of these three aPLs is a requirement 
to fulfill criteria for the classification of APS, along with at least one of the major clinical manifestations 
[1,2]. 
Several authors have suggested that testing for new aPL specificities may help to identify the syndrome 
in patients with thrombosis or pregnancy losses in whom APS is strongly suspected but conventional 
aPL are repeatedly negative [3], the so-called ‘seronegative APS’ [4]. In addition, several autoantibodies 
directed to proteins of the coagulation cascade (i.e. prothrombin) or their complex with phospholipids 
(i.e. phosphatidylserine–prothrombin) have been proposed to be relevant to APS [5], although the 
clinical utility and their diagnostic value remain undecided. Unfortunately, most of the studies are based 
on testing for the distinct clinical significance of a particular antibody instead of establishing the 
potential additional value of an individual test or a combination of tests in the recognition of APS. 
We designed this study to evaluate the clinical accuracy of known aPL specificities, both individually 
and in combination, in a wide cohort of patients with systemic lupus erythematosus (SLE) in an attempt 
to identify a panel of tests, or their combinations, that may provide the best accuracy for diagnosing 
APS. 
 
Patients and methods 
Patients 
This study included 230 consecutive patients (218 women, mean age 42.7 ± 11.9 years, mean disease 
duration 12.2 ± 8.7 years), all fulfilling the 1982 criteria for SLE [6]. Of these, 61 patients fulfilled 
criteria for definite APS [1,2] and 55 were positive for aPL without fulfilling criteria. 
Overall, 86 patients had a history of thrombosis (40 arterial, 26 venous and 20 both arterial and venous 
thrombosis). Out of 145 women who had ever been pregnant, 39 had a history of miscarriages (before 
the 10th week of gestation) and 36 a history of fetal death (after the 10th week of gestation). 
Demographic data are summarized in Table 1. 
Ethical approval was obtained from the Guy’s and St Thomas’ Ethics Committee and all patients 
involved in this study gave their written consent. 
Methods 
All patient samples were obtained during a routine appointment. All aPL tests were performed on the 
same sample obtained on the day of the appointment after written consent was given. 
 LA determination Plasma samples were tested for the presence of LA according to the recommended 
criteria from the ISTH Subcommittee on Lupus Anticoagulant-Phospholipid-dependent antibodies [7], 
using the Automated Coagulation Laboratory (ACL) 300R (Instrumentation Laboratory, Milan, Italy). 
All samples were screened using the activated partial thromboplastin time (aPTT – IL test™ APTT-SP; 
Instrumentation Laboratory). Ratios higher than 1.10, which did not correct with the 50:50 mixture with 
normal plasma, were considered as suggestive of LA and subjected to dRVVT testing. 
The dilute Russell viper venom time (dRVVT) coagulation test was performed using Diagen Russell’s 
viper venom (Diagnostic Reagents Ltd, Oxon, UK) as described by Thiagarajan et al. [8] in all samples. 
Both screen and confirm steps were performed. Ratios higher than 1.10, which did not correct with the 
50:50 mixture with normal plasma but decreased by 10% or more when using excess of phospholipids, 
were diagnostic of LA. 
 Other aPL testing aPL were tested for IgG and IgM isotypes. The aCL ELISA was performed 
according to the standardized technique [9]. Anti-β2GPI was detected by ELISA as described previously 
[10], using purified human β2GPI (Yamasa, Japan) coated on irradiated microtitre plates (Nunc 
Maxisorp, Denmark). Antibodies to prothrombin were tested by two methods, the aPT ELISA, using 
purified human prothrombin (Enzyme Research Laboratories, UK) coated on irradiated plates, as 
previously detailed [11], and the aPS/PT ELISA using purified human prothrombin/phosphatidylserine 
complex as antigen, as previously reported [12]. 
aPE were tested as described by Sanmarco et al. [13] using bovine brain phosphatidylethanolamine 
(Sigma-Aldrich, UK) [14]. 
The cut-off value for each aPL assay was determined by the 99th percentile of ≥ 100 healthy controls. 
 
Statistical analysis 
Mann–Whitney U, Fisher’s exact or chi-square tests were applied as appropriate. P-values < 0.05 were 
considered significant. Comparisons between groups were expressed as odds ratio with its 95% 
confidence interval (OR [95% CI]), where a lower limit > 1.0 was considered significant. Sensitivity, 
specificity and positive and negative predictive values (PPV and NPV) were calculated to compare the 
accuracy between the different combinations of tests. Areas under the receiver operating characteristic 
(ROC) curve (AUC) of different combinations of the six aPL tested were computed. The diagnostic 
accuracy for each combination of tests was also assessed based on Youden’s J statistic (Youden’s 
index). All statistical analyses were performed using SPSS 17.0 (IBM, Chicago, IL, USA). 
Results 
Prevalence of all aPL tested is shown in Table 2. 
Table 2.  Prevalence of aPL in SLE  
Patients were considered positive for aPL when any (at least one) of the six tested antibodies was 
positive. Overall, 61 patients were diagnosed as having APS and 55 patients showed positivity for LA, 
aCL and/or anti-β2GPI in the absence of clinical events attributable to APS. When increasing the panel 
to six aPL, 177 patients (77%) were found to be positive for at least one of them. 
Diagnostic performances for the combination of LA and aCL (Sapporo Laboratory Criteria) and 
LA + aCL + anti-β2GPI (Sydney revised Criteria) were evaluated and compared with other possible 
combinations of tests (Tables 3 and 4). 
Table 3.  Diagnostic accuracy evaluated by AUD through ROC  
The ‘Sapporo combination’ (LA + aCL) gave a sensitivity of 80%, a specificity of 44%, a PPV of 23% 
and an NPV of 91% for APS diagnosis (both thrombosis and/or pregnancy loss). The ‘Sydney 
combination’ showed a similar diagnostic performance (Table 4). Although the use of more than three 
tests increased the overall sensitivity for APS diagnosis to over 80%, it deeply impacted on the 
specificity, which dropped to under 40% for all the combinations (LA + aCL + anti-β2GPI + aPS/PT = 
38%; LA + aCL + anti-β2GPI + aPT = 35%; LA + aCL + anti-β2GPI + aPE = 36%). Among the 
different combinations of three available tests, LA + anti-β2GPI + aPS/PT had the best specificity 
(Table 4). 
When analyzing APS diagnosis, the AUC for Sydney criteria was 0.612 (Fig. 1). The higher values of 
the AUC were achieved by the combination of LA + anti-β2GPI + aPT/PS (AUC 0.712, OR 3.89 [95% 
CI 1.96–5.38], P = 0.0001) (Fig. 1). 
The Sapporo combination (aCL + LA) gave a sensitivity of 76%, a specificity of 47%, a PPV of 46% 
and an NPV of 77% for thrombosis. The Sydney combination had an equivalent diagnostic performance 
for thrombosis (Table 4). As observed for APS diagnosis, the use of more than three tests showed an 
increase in the overall sensitivity for thrombosis to over 80%, but reduced the specificity to around 40% 
(LA + aCL + anti-β2GPI + aPS/PT = 41%; LA + aCL + anti-β2GPI + aPT = 41%; LA + aCL + anti-
β2GPI + aPE = 40%). Among the different combinations of three available tests, LA + anti-
β2GPI + aPS/PT was confirmed as having the best specificity for thrombosis (69%) when compared 
with an average 47% for all the other combinations of three tests (range 37%–62%). 
For pregnancy loss, only patients who fulfilled criteria [2] (i.e. ≥ 3 miscarriages and/or ≥ 1 fetal death) 
were analyzed. The Sapporo combination gave a sensitivity of 68%, a specificity of 44%, a PPV of 52% 
and an NPV of 60%. The Sydney combination had identical diagnostic performance (Table 4). 
As noted before, the use of more than three tests increased the overall sensitivity for pregnancy loss to 
over 80%, but decreased the specificity to 36% for LA + aCL + anti-β2GPI + aPS/PT and 34% for 
LA + aCL + anti-β2GPI + aPT and LA + aCL + anti-β2GPI + aPE. Among the different combinations, 
LA + anti-β2GPI + aPS/PT was confirmed as having the best specificity for pregnancy loss (61%) when 
compared with an average 43% for all the other combinations (range 33%–56%). 
 
In addition, this combination of LA + anti-β2GPI + aPS/PT had a better diagnostic performance for 
pregnancy loss than the Sapporo and Sydney criteria combinations, both in sensitivity and specificity 
(Table 2). 
The AUC data were confirmed by Youdon’s Index (YI), showing best diagnostic performances for the 
LA + anti-β2GPI + aPS/PT combination for APS, thrombosis and PL (AUC 0.712, OR 3.73 [95% CI 
1.82–5.38], P = 0.0001, YI = 0.32; AUC 0.709, OR 3.75 [95% CI 2.13–6.62], P = 0.0001, YI = 0.37 and 
AUC 0.677, OR 4.82 [95% CI 2.17–10.72], P = 0.0007, YI = 0.38, respectively). 
In addition, we performed a further analysis to investigate the clinical risk in the presence of single, dual 
or multiple positivity including LA + anti-β2GPI + aPS/PT. As shown in Fig. 2, concomitant triple 
positivity for LA, aβ2GPI and aPS/PT was more strongly associated with clinical events (thrombosis 
and/or pregnancy loss) when compared with double or single positivity (OR 23.2 [95% CI 2.57–46.17] 
vs. OR 7.32 [95% CI 2.21–25.97], OR 5.67 [95% CI 2.12–17.01], OR 3.11 [95% CI 1.56–7.77] for 
single positivity for LA, or aPS/PT or aβ2GPI, respectively) (Fig. 2). 
 
Discussion 
Vascular thrombosis and pregnancy morbidity were described as the main clinical features of APS in the 
early 1980s [15], deep venous thrombosis and pregnancy losses being the most common. As both these 
events are relatively common in the general population and in subjects with autoimmune diseases, 
correctly classifying patients with APS can be a complex task. In addition, patients who experience 
thrombosis or recurrent miscarriages are classified as having APS based exclusively on the presence of 
routinely tested aPL (i.e. aCL, LA and in some laboratories but not all, anti-β2GPI). Therefore, 
laboratory testing for aPL has an extraordinarily critical role in the clinical setting. 
In clinical practice, aCL and anti-β2GPI antibodies detected by ELISA and LA detected by clotting 
assays have been the most established tests for diagnosis of APS [16]. However, the family of aPL is 
continuously expanding to include a heterogeneous group of autoantibodies whose specificity is directed 
against phospholipid binding proteins or their complex with phospholipids. In addition, a wide 
variability in strength of association between routine and newly tested aPL and the clinical 
manifestations of APS have also been reported. In the search for better markers for APS, most of the 
attention has been focused on describing new specificities for aPL and very little on the evaluation of 
the potential best combination of the already available tests. 
Recent studies have shown that the risk of thrombotic events increases with the number of positive tests 
in APS patients [17–19] and aPL carriers [20]. These studies focused on the routinely tested aPL (i.e. 
aCL, anti-β2GPI and LA). Pengo et al. [21] suggested that positivity in a single test among LA, aCL and 
aβ2GPI would call the diagnosis of APS into question and, conversely, suggested that triple positivity is 
strongly associated with thrombosis and pregnancy loss [20,21]. 
In this study, we retrospectively analyzed a large series of SLE patients, and assessed the potential 
clinical usefulness of combining routinely tested aPL with new aPL specificities in an attempt to find a 
profile that will identify patients at higher risk of APS. Among the 23 possible combinations of the six 
aPL tested, LA + anti-β2GPI + aPS/PT had the best diagnostic accuracy for APS as a whole, and for 
both thrombosis and pregnancy loss (PL). When comparing it to the combination suggested by the 
current criteria and previous studies [18] and all the other tested combinations, positivity for LA + anti-
β2GPI + aPS/PT had the best diagnostic performance in terms of specificity and PPV in our SLE cohort. 
In this case, the increased specificity was due to anti-β2GPI being a more specific marker than aCL [22]. 
Besides, some of the proposed combinations, namely the combination of four tests (Sydney revised 
laboratory criteria plus aPE and/or aPT and/or aPT/PS, respectively) presented AUC under the value 
0.6, suggesting that the sole increase in sensitivity given by the use of more tests does not improve the 
diagnostic performance. 
In addition, we found that simultaneous positivity, double or triple, was detected more frequently in 
patients with thrombosis. Interestingly, also in the combination LA + anti-β2GPI + aPS/PT, each further 
aPL positivity detection increased the risk of thrombosis, with OR ranging from three to seven for the 
single positivity for anti-β2GPI and aPS/PT, respectively, to 23 for the triple positivity (Fig. 2). We 
found that triple positivity for LA + anti-β2GPI + aPS/PT was the strongest risk factor for thrombosis 
and/or pregnancy loss (OR 23.2) even when comparing it with data reported in the current literature 
about triple positivity for LA + aCL + anti-β2GPI (OR 14.9) [18]. These findings are in line with data 
recently reported by Otomo et al. showing that the inclusion of aPS/PT in the battery of aPL tests 
allowed a better quantification of the thrombotic risk [23]. 
It is also true that our model has some limitations as we used dichotomized variables. This strategy 
simplified the comparison of the different combinations of tests. Nevertheless, the use of titer for each 
aPL test as continuous variable did not provide more refined information and confirmed the results 
obtained by using dichotomized variables (data not shown). 
Thus, our data confirm that triple positivity for aPL identifies patients at high risk of thrombotic events 
and obstetric complications. The concomitant triple positivity for LA + anti-β2GPI + aPS/PT is not only 
strongly associated with thrombosis and pregnancy loss, but shows a higher diagnostic accuracy than 
that of aCL + LA + anti-β2GPI at least in this cohort of patients with SLE. 
In summary, combining LA + anti-β2GPI + aPS/PT not only improves the diagnostic power but seemed 
to be helpful in stratifying the risk of an event, according to the aPL profile. 
Our study may lead to a differentiated aPL testing approach (aPL screening and aPL confirm), to be 
confirmed in larger prospective studies. 
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Figure 1. 
 
 
(A) Receiver operating characteristic (ROC) curves of the 23 different aPL combinations. 
Sensitivity and specificity were calculated according to the presence of a history of thrombosis 
and/or PL. (B) ROC curves for Sapporo and Sydney criteria for APS in comparison with the 
combination including LA, aβ 2GPI and aPS/PT. AUC are 0.612, 0.612 and 0.712, 
respectively. 
 
 
 
 
 
 
 
Figure2. 
 
Odd ratios for thrombosis are estimated according to aPL profile, showing that each further positivity 
increases the risk of event. Multiple aPL positivity, particularly the triple association of LA and aβ2GPI 
and aPS/PT further increases the risk of thrombosis 
 
 
 
 
 
 
  
 
 
 
 
 
 
Table 1.  Demographic characteristics of SLE  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Table 2.  Prevalence of aPL in SLE  
 
aPL* 
SLE  
n = 230 (%) 
LA 56 (25) 
aCL IgG/IgM 126 (56) 
 aCL IgG 111 (49) 
 aCL IgM 46 (20) 
Anti-β2GPI IgG/IgM 48 (21) 
 Anti-β2GPI IgG 38 (16) 
 Anti-β2GPI IgM 14 (6) 
aPE IgG/IgM 92 (41) 
 aPE IgG 79 (35) 
 aPE IgM 24 (10) 
aPT IgG/IgM 68 (30) 
 aPT IgG 57 (25) 
 aPT IgM 15 (6) 
aPL* 
SLE  
n = 230 (%) 
aPS-PT IgG/IgM 68 (30) 
 aPS-PT IgG 55 (24) 
 aPS-PT IgM 33 (14) 
1. *Some patients were positive for more than one 
antibody and/or isotype. IgG/M, IgG and/or IgM; aPE, anti-
phosphatidylethanolamine; aCL, anticardiolipin antibodies; 
anti-β2GPI, antibodies to β2 glycoprotein I; aPT, antibodies 
to prothrombin in solid phase; aPS-PT, antibodies to 
phosphatidylserine-prothrombin complex; LA, lupus 
anticoagulant. 
 
 
Table 3.  Diagnostic accuracy evaluated by AUD through ROC  
Antibodies 
APS Thrombosis Pregnancy loss 
AU
C 
OR 
[95% 
CI] 
P 
AU
C 
OR 
[95% 
CI] 
P 
AU
C 
OR 
[95% 
CI] 
P 
LA + aCL 0.612 3.22 
[1.41–
7.36] 
0.004
1 
0.620 3.04 
[1.67–
5.52] 
0.000
2 
0.613 1.70 
[0.99–
2.91] 
0.054
3 
LA + aCL + anti-
β2GPI 
0.612 3.22 
[1.41–
7.36] 
0.004
1 
0.620 3.04 
[1.67–
5.52] 
0.000
2 
0.613 1.70 
[0.99–
2.91] 
0.054
3 
LA + aCL + anti-
β2GPI + aPS/PT 
0.610 1.69 
[0.89–
2.96] 
NS 0.599 3.05 
[1.61–
5.75] 
0.000
4 
0.620 4.03 
[1.50–
10.79] 
0.003
3 
LA + aCL + anti-
β2GPI + aPT 
0.594 1.74 
[0.91–
3.01] 
NS 0.601 2.95 
[1.56–
5.58] 
0.000
7 
0.584 2.46 
[1.03–
5.88] 
0.038
6 
LA + aCL + anti-
β2GPI + aPE 
0.584 1.82 
[0.84–
4.62] 
NS 0.599 2.82 
[1.51–
5.27] 
0.000
9 
0.592 2.46 
[1.03–
5.88] 
0.038
6 
Antibodies 
APS Thrombosis Pregnancy loss 
AU
C 
OR 
[95% 
CI] 
P 
AU
C 
OR 
[95% 
CI] 
P 
AU
C 
OR 
[95% 
CI] 
P 
LA + aCL + aPS/PT 0.610 1.70 
[0.88–
2.97] 
NS 0.599 3.04 
[1.67–
5.52] 
0.000
2 
0.620 4.03 
[1.50–
10.79] 
0.003
3 
LA + aCL + aPE 0.584 1.57 
[0.92–
2.69] 
NS 0.599 2.82 
[1.51–
5.27] 
0.000
9 
0.592 2.46 
[1.03–
5.88] 
0.038
6 
LA + aCL + aPT 0.594 1.70 
[0.99–
2.91] 
NS 0.601 2.95 
[1.56–
5.58] 
0.000
7 
0.584 2.46 
[1.03–
5.88] 
0.038
6 
LA + anti-
β2GPI + aPS/PT 
0.712 3.73 
[1.82–
5.38] 
0.000
1 
0.709 3.75 
[2.13–
6.62] 
0.000
1 
0.677 4.82 
[2.17–
10.72] 
0.000
7 
LA + anti-
β2GPI + aPT 
0.650 3.01 
[1.75–
5.19] 
0.001 0.652 3.64 
[2.07–
6.42] 
0.000
1 
0.646 3.46 
[1.653–
7.36] 
0.000
8 
LA + anti-
β2GPI + aPE 
0.608 2.17 
[1.28–
3.67] 
0.003
8 
0.607 2.51 
[1.43–
4.40] 
0.001
1 
0.625 3.00 
[1.38–
6.50] 
0.004
1 
aCL + anti-
β2GPI + aPS/PT 
0.614 1.76 
[1.04–
2.99] 
0.035
7 
0.606 2.79 
[1.54–
5.08] 
0.000
6 
0.612 3.13 
[1.31–
7.46] 
0.007
6 
aCL + anti-
β2GPI + aPT 
0.591 1.68 
[0.99–
2.85] 
0.052 0.600 2.62 
[1.45–
4.73] 
0.001
2 
0.572 1.94 
[0.89–
4.23] 
NS 
aCL + anti-
β2GPI + aPE 
0.570 1.52 
[0.90–
2.58] 
NS 0.587 2.33 
[1.30–
4.18] 
0.004
2 
0.572 1.94 
[0.89–
4.23] 
NS 
Anti-
β2GPI + aPS/PT + aP
T 
0.658 3.63 
[2.07–
6.36] 
0.000
1 
0.643 3.35 
[1.91–
5.88] 
0.000
1 
0.643 3.38 
[1.59–
7.19] 
0.001 
aPT + aPS/PT + aCL 0.590 1.70 
[1.00–
2.89] 
0.048
2 
0.589 2.58 
[1.38–
4384] 
0.002
6 
0.578 2.34 
[0.98–
5.60] 
0.051
6 
Antibodies 
APS Thrombosis Pregnancy loss 
AU
C 
OR 
[95% 
CI] 
P 
AU
C 
OR 
[95% 
CI] 
P 
AU
C 
OR 
[95% 
CI] 
P 
aPT + aPS/PT + LAC 0.618 2.31 
[1.36–
3.93] 
0.001
8 
0.609 2.58 
[1.47–
4.54] 
0.000
9 
0.619 2.87 
[1.32–
6.22] 
0.006 
aPT + aPE + anti-
β2GPI 
0.581 2.00 
[1.18–
3.39] 
0.009
9 
0.579 1.97 
[1.14–
3.42] 
0.015 0.582 1.99 
[0.96–
4.10] 
NS 
aPT + aPE + aCL 0.555 1.47 
[0.87–
2.49] 
NS 0.570 2.12 
[1.15–
3.90] 
0.015
1 
0.553 1.17 
[0.76–
3.82] 
NS 
aPT + aPE + LAC 0.592 2.12 
[1.25–
3.59] 
0.005
1 
0.593 2.41 
[1.33–
4.35] 
0.003
2 
0.602 2.72 
[1.18–
6.23] 
0.015
3 
Anti-
β2GPI + aPE + aPS/P
T 
0.627 2.49 
[1.46–
4.24] 
0.000
7 
0.609 2.58 
[1.47–
4.54] 
0.000
9 
0.632 3.29 
[1.48–
7.32] 
0.002
4 
aPE + aPS/PT + LAC 0.610 2.08 
[1.23–
3.52] 
0.006
2 
0.612 2.65 
[1.50–
4.68] 
0.000
7 
0.611 2.68 
[1.24–
5.81] 
0.010
4 
aPE + aPS/PT + aCL 0.581 1.59 
[0.94–
2.81] 
NS 0.582 2.44 
[1.30–
4.57] 
0.004
9 
0.591 2.81 
[1.12–
7.07] 
0.023
4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Table 4.  Sensitivity, specificity, PPV, NPV and Youden’s Index* for APS diagnosis, thrombosis 
and pregnancy loss for each combination of aPL  
 
 
 
